![Thomas Sabia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Thomas Sabia formerly worked at Quince Therapeutics SpA, as Chief Commercial Officer from 2022 to 2023 and Quince Therapeutics, Inc., as Chief Commercial Officer from 2022 to 2025.
Mr. Sabia received his undergraduate degree and Masters Business Admin degree from Salisbury State University.
Ehemalige bekannte Positionen von Thomas Sabia
| Unternehmen | Position | Ende |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Corporate Officer/Principal | 28.02.2025 |
EryDel SpA
 EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Corporate Officer/Principal | 01.10.2023 |
Ausbildung von Thomas Sabia
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
5
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Salisbury State University
 Salisbury State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EryDel SpA
EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Health Technology |
Quince Therapeutics, Inc.
 Quince Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders and Alzheimer’s diseases | Health Technology |
